That additional institutions approached IDRA and wanted in? I say that due to the warrants being issued as well. Looks like a pre-planned deal to either get Baker Bros more shares, or another large new institution onboard, perhaps FMR or Orbimed?
$7.68 next stop?
They don't get paid until the stock price is above their options. It's that simple. Any questions?
Part of their sign on package with Idera. Check the filings. They wouldn't have joined if the stock wasn't headed much much higher. Common sense stuff.
Just posted to Edgar. Pillar converted 1,124,260 shares of Series D Convertible Preferred Stock into 6,266,175 shares of IDRA Common Stock. That's a pretty big vote of confidence from insiders.
You think they are in it to day trade or do they know something the rest of us don't?
Seems like a reasonable question to ask yourself before buying or selling IDRA shares.
Someone posted a clip from an SEC filing to this effect, but I can't locate the post to follow up on it. Can some follow up with details or a pointer. This peaked my interest. Thanks.
Excellent thread guys. Baker Bros is a huge factor here, but I think those two execs they brought on from Genzyme really tell you where Idera is headed. I think $40-50 a share by the end of this year is achievable.
Reading the filing.
Besides Baker Bros, the other 2 13F filings to watch for are Orbimed and/or FMR. If either of those added shares you'll want to quickly add as many shares as you can before word spreads. I check the filings multiple times each day. As of this evening Vanguard opened a new position over a million shares of IDRA. Everything else - bashers, share price, etc. is just noise right now. Keep your eye on the prize - $100 by years end.
Buy all you can below $5. The two Genzme execs they brought on board last week have compensation packages with stock option strikes at $5.04 and $5.30 (see the SEC filings from 1/9). Rest assured they wouldn't have joined if they weren't going to get paid.
Look at the Form 4 option grant and subsequent S-3 filing today. Louis Brenner doesn't yet appear on Idera's "About Us" page, so presumably this is a new addition to the team? That's certainly bullish. Perhaps in preparation for moving IMO-8400 into Phase 3? Good stuff!
I feel bad for those that got stopped out today. Let the move up continue!
Way way up again today! And the accumulation continues...
As the title says.
Outstanding find. Thanks. So do we have reason to believe that this genetic mutation has an excellent response rate to 8400? I love how these guys are zeroing in on very specific subclass of disease. Best way of ensuring trial success.
Humira, a treatment for rheumatoid arthritis, psoriasis, Crohn's disease and other conditions, is the world's top-selling prescription drug. Sales have risen steadily since it was introduced in 2002.
The Best Selling Drugs of All Time; Humira Joins The Elite
Comment Now Follow Comments
When Abbott announced its full-year results last week, its anti-TNF inhibitor product Humira delivered a stronger-than-expected 23.1 percent year-on-year increase in Q4 sales (recorded at $2.7 billion). Annual sales for 2012 stood at $9.3 billion, cementing the status of Humira as one of the biggest selling products of all time.
Measured in terms of peak annual sales, Humira revenues in 2012 were marginally below the combined sales of Plavix recorded by Bristol-Myers Squibb and Sanofi in 2011. However, while Plavix revenues are now undergoing a dramatic decline following US patent expiry last year, Humira continues to act as a key growth product for Abbott/AbbVie, and is expected to do so for some time.
Based on an annualised Q4 2012 performance, Humira sales would stand at $10.7 billion; thus full-year revenues for 2013 can be expected to easily outstrip those of Plavix and move closer to the peak $13.7 billion figure set by Pfizer‘s Lipitor.